Avricore Signs Multi-Year Abbott Deal for UK Point-of-Care Testing
AVCRF is trading near its 52-week low of $0.001 (0.0% above the low) on light trading volume (0.3× avg).
Summary
Avricore Health signed a multi-year collaboration with Abbott to distribute point-of-care testing products in UK pharmacies, alongside Q2 results showing a 74% revenue decline and going concern risk.
Key Events · M&A and Partnerships · AVCRF
-
Abbott Collaboration Agreement Signed
HealthTab Ltd entered a multi-year agreement with Abbott to distribute the Afinion 2 Analyzer in NHS-linked UK pharmacies for HbA1c and lipid testing, establishing a framework for expansion.
-
Q2 Revenue Up 170% Quarter-over-Quarter
Revenue reached C$77,595 in Q2 2026, up 170% from C$28,692 a year earlier, driven by UK ramp-up; however, H1 revenue fell 74% to C$121,910 due to the Shoppers Drug Mart contract loss.
-
Going Concern Risk Persists
The company reported an accumulated deficit of C$34,743,529 and negative operating cash flow of C$502,531 for H1 2026, with management citing conditions that may cast substantial doubt on its ability to continue as a going concern.
-
3.3M Stock Options Granted
The board approved 3,300,000 options exercisable at CAD $0.06 per share, vesting quarterly over five years, for directors, officers, employees, and consultants.
Analysis · AVCRF · Life Sciences
Avricore's HealthTab subsidiary has entered a formal multi-year collaboration with Abbott to distribute the Afinion 2 Analyzer in NHS-linked UK pharmacies for HbA1c and lipid testing. This is the company's most significant commercial milestone to date and directly addresses the revenue collapse caused by the loss of its Shoppers Drug Mart contract in 2025. The deal provides a credible path to rebuild revenue in the UK, where HealthTab already operates 59 systems and has screened over 3,500 patients. However, the company remains in a precarious financial position: H1 2026 revenue fell 74% year-over-year to C$121,910, the accumulated deficit stands at C$34.7 million, and the financial statements include going concern language. The Abbott agreement is a genuine strategic win, but it is unproven at scale and the company's cash runway remains dependent on future financing.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVCRF was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $0.00 to $0.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.